[en] Objective: Although adverse events are a key factor in compliance, their evolution during treatment with antidepressants is poorly documented. Therefore, the time course of adverse events during 6 months of antidepressant treatment was investigated. Method: 85 psychiatric outpatients with a DSM-IV diagnosis of major depressive disorder (with the exclusion of other DSM-IV Axis I disorders) were enrolled between September 2002 and March 2003 in a multicenter, randomized, double-blind trial with selective serotonin reuptake inhibitors (fluoxetine [N = 421 and paroxetine [N = 43]). At each visit, the presence and severity of treatment-emergent adverse events were assessed systematically using the UKU Side Effect Rating Scale (UKU). General linear mixed modeling was used to investigate the predictors of the time course of adverse events. Results: Overall, the number of at least moderately severe adverse events decreased with time. More severely depressed patients reported overall more (at least moderately severe) adverse events than less severely depressed patients (p =.0002), but the decrease in reported adverse events was comparable over time. Men (N = 30) and women (N = 55) reported initially the same number of at least moderately severe adverse events, but the habituation was more rapid in men (p <.0001). Completers (N = 58) and dropouts (N = 27) did not differ initially, but completers' habituation was more rapid (p =.014). The habituation of adverse events was also more rapid in recurrent than in first-episode patients but only in men (p =.0025). Conclusion: The time course of adverse events varies with the severity of depression, sex, completer or dropout status, and recurrent versus first-episode depression.
Disciplines :
Treatment & clinical psychology
Author, co-author :
Demyttenaere, K.
Albert, Adelin ; Université de Liège - ULiège > Département des sciences de la santé publique > Informatique médicale et biostatistique
Mesters, P.
Dewé, Walthère ; Université de Liège - ULiège > Analyse des médicaments
De Bruyckere, K.
Sangeleer, M.
Language :
English
Title :
What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors?
Demyttenaere K. Compliance during treatment with antidepressants. J Affect Disord 1997;43:27-39
Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand 2002;105:164-172
Bull S, Hu XH, Hunkeler EM, et al. Discontinuation of use and switching of antidepressants. JAMA 2002;288:1403-1409
Lin EHB, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy: influence of patient-physician communication. Med Care 1995;33:67-74
Demyttenaere K, Enzlin P, Dewe W, et al. Compliance with antidepressants in a primary care setting, 1: beyond lack of efficacy and adverse events. J Clin Psychiatry 2001;62(suppl 22):30-33
Kobak KA, Taylor L, Katzelnick DJ, et al. Antidepressant medication management and Health Plan Employer Data Information Set (HEDIS) criteria: reasons for nonadherence. J Clin Psychiatry 2002;63:727-732
Maddox JC, Levi M, Thompson C. The compliance with antidepressants in general practice. J Psychopharmacol 1994;8:48-53
Hotopf M, Hardy R, Lewis G. Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. BMJ 1997;170:120-127
Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000;58:19-36
MacGillivray S, Arroll B, Hatcher S, et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ 2003;326:1014-1019
Trindade E, Menon D, Topfer LA, et al. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ 1998;159:1245-1252
Wade A, Lemming OM, Hedegaard KB. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002;17:95-102
Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002;63:331-336
Zajecka J, Amsterdam JD, Quitkin FM, et al. Changes in adverse events reported by patients during 6 months of fluoxetine therapy. J Clin Psychiatry 1999;60:389-394
Bull SA, Hunkeler EM, Lee JY, et al. Discontinuing or switching selective serotonin reuptake inhibitors. Ann Pharmacother 2002;36:578-584
Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU Side Effect Rating Scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987;76(suppl 334):1-100
Masand PS, Gupta S. Selective serotonin-reuptake inhibitors: an update. Harv Rev Psychiatry 1999;7:69-84
Linden RD, Wilcox CS, Cavanaugh E, et al. Are selective serotonin reuptake inhibitors well tolerated in somatizing depressives? Psychopharmacol Bull 1994;30:151-156
Nemeroff CB, Schatzberg AF, Goldstein DJ, et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002;36: 106-132
Hildebrandt MG, Steyerberg EW, Stage KB, et al. Are gender differences important for the clinical effects of antidepressants? Am J Psychiatry 2003;160:1643-1650
Yonkers KA, Brawman-Mintzer O. The pharmacologic treatment of depression: is gender a critical factor? J Clin Psychiatry 2002;63:610-615